GeETA Upadhyay, Ph.D.

B.S. Lucknow University, Chemistry, Statistics & Mathematics

M.Sc. Lucknow University, Organic Chemistry

Ph.D. Sanjay Gandhi Postgraduate Institute of Medical Sciences; University of Ulm, Breast Cancer

Research Fellow, University of Texas Health Science Center, Neurological Diseases 

Research Fellow, Breast Cancer, National Cancer Institute, Bethesda, MD

Research Fellow, Gastrointestinal Cancer, Harvard Medical School, Boston, MA

Research Fellow, Breast Cancer, Georgetown University, Washington, DC

Adjunct Professor, Georgetown University, Washington, DC

Associate Professor, Uniformed Services University of the Health Sciences, Bethesda, MD

Dr. Upadhyay received her award-winning PhD degree in 2003 from Molecular Endocrinology of breast cancer at Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. Dr. Upadhyay received her postdoctoral training at Harvard Medical School, Boston, National Institute of Health, Bethesda, and University of Texas Health Science Center of San Antonio, USA.

Dr. Upadhyay is an Associate Professor in the Department of Pathology and in the Department of Molecular and Cellular Biology at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, USA. Dr. Upadhyay is an active member of DOD funded Breast Cancer Research Program of John P. Murtha Cancer Center at USUHS. She also holds adjunct appointment at Georgetown University Medical Center. Dr. Upadhyay plays an active role in Faculty Senate of Uniformed Services University as President Elect. Dr. Upadhyay serves as a mentor in Sallie Rosen Kaplan (SRK) Fellowship for women scientists in cancer research.

The research interest in Dr. Upadhyay’s lab is to identify novel diagnostic markers and develop targeted therapies in solid cancers such as triple negative breast cancer (TNBC) and pancreatic cancer. The lab had identified that the novel gene family of LY6 proteins play important role in cancer progression, immune escape and determine the survival outcome in pancreatic and TNBC cancer. Current projects are focused on understanding the mechanistic basis of Ly6K action on the TGF-beta and tumor immune escape pathways in breast cancer. The novel drug development aspect of the project is focused on testing the small molecule binders of Ly6K in treatment of triple negative breast cancer.